March 6-8, 2008 (Nice, France)

Course venue: Grand Hotel Aston 12, Rue Felix Faure 06002 Nice - France  www.hotel-aston.com    Registration form

---

Organising Committee

Stuart Elborn (Belfast, UK)
Anders Lindblad (Gothenburg, Sweden)
Harm Tiddens (Rotterdam, the Netherlands)

---

Faculty

Kris de Boek (Leuven, Belgium)
Stuart Elborn (Belfast, UK)
Christopher Goss (Seattle, USA)
John R.W. Govan (Edinburgh, UK)
Eithan Kerem (Jerusalem, Israel)
Anders Lindblad (Goteborg, Sweden)
Francesco Pasinelli (Milan, Italy)
Rosalind Smyth (Liverpool, UK)
Harm Tiddens (Rotterdam, the Netherlands)
Julian Zielenski (Toronto, Canada)

---

Educational Aims

• To update on the importance of modifier on the disease severity and outcome of CF
• To update knowledge of the roles of CFTR in the pathophysiology of CF
• To update on the current concept of host microorganism interaction. To understand the difference between pathogens and less pathogenic microorganisms; the role of viruses; the value of resistance in vivo and in vitro; factors that affect the effectiveness of antibiotics (sputum, aerosolised antibiotics, mechanisms of resistance)
• To update knowledge on the diagnostic algorithms in the diagnosis of atypical cases of CF
• To understand the basics of evidence-based medicine in CF and understanding what answers the literature in CF can give and what answers are not yet available
• To be able to understand how relevant the results of large-scale randomised controlled trials are for an individual
• To understand the value of databases at the level of a CF centre, and at the national and at the international level
• To have understanding of how inflammation contributes to the severity of CF lung disease and what could be strategies to treat this inflammation
• To understand the complexity of drug development programmes; to understand the basics of pharmacoeconomics and the role of Phase I, II, III and IV trials
• To improve skills in designing clinical trials and writing grant applications
• To be aware of the opportunities to raise funding for CF-related research in a highly competitive world

---

Target audience

• (Paediatric) pulmonologists
• CF clinicians
• Internists who are involved in CF care

---

Course goals

At the end of the course, participants will:

• Have state-of-the-art knowledge of important issues in the pathophysiology of CF lung disease
• Have state-of-the-art knowledge on the diagnosis of (a)typical CF
• Understand the strengths and weaknesses of evidence based on medicine
• Understand the basics of running research trials in CF
• Be able to put together a protocol
• Be able to understand the strengths and weaknesses of various CF database formats
• Understand key issues in health economics
• Have learned about the importance and future perspective of CF organisations at a regional, national and international level